

# UCLA

## UCLA Previously Published Works

### Title

A Genome-Wide Association Study of Vertical Cup-Disc Ratio in a Latino Population  
GWAS of Vertical Cup-Disc Ratio in Latino Individuals

### Permalink

<https://escholarship.org/uc/item/7sm9j8pr>

### Journal

Investigative Ophthalmology & Visual Science, 58(1)

### ISSN

0146-0404

### Authors

Nannini, Drew R  
Torres, Mina  
Chen, Yii-Der I  
[et al.](#)

### Publication Date

2017-01-06

### DOI

10.1167/iovs.16-19891

Peer reviewed

# A Genome-Wide Association Study of Vertical Cup-Disc Ratio in a Latino Population

Drew R. Nannini,<sup>1</sup> Mina Torres,<sup>2</sup> Yii-Der I. Chen,<sup>3</sup> Kent D. Taylor,<sup>3</sup> Jerome I. Rotter,<sup>3</sup> Rohit Varma,<sup>2</sup> and Xiaoyi Gao<sup>1</sup>

<sup>1</sup>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States

<sup>2</sup>USC Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles, California, United States

<sup>3</sup>Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute and Department of Pediatrics and Medicine at Harbor-UCLA, Torrance, California, United States

Correspondence: Xiaoyi Gao, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA; rgao@uic.edu.

Submitted: May 9, 2016

Accepted: November 16, 2016

Citation: Nannini DR, Torres M, Chen YDI, et al. A genome-wide association study of vertical cup-disc ratio in a Latino population. *Invest Ophthalmol Vis Sci.* 2017;58:87-95. DOI:10.1167/iops.16-19891

**PURPOSE.** Vertical cup-disc ratio (VCDR) is used as a clinical assessment measure to identify and monitor glaucomatous damage to the optic nerve. Previous genetic studies conducted in European and Asian populations have identified many loci associated with VCDR. The genetic factors in other ethnic populations, such as Latino, influencing VCDR remain to be determined. Here, we describe the first genome-wide association study (GWAS) on VCDR in Latino individuals.

**METHODS.** We conducted this GWAS on VCDR using 4537 Latino individuals who were genotyped by using either the Illumina OmniExpress BeadChip (~730K markers) or the Illumina Hispanic/SOL BeadChip (~2.5 million markers). Study subjects were 40 years of age and older. Linear regression, adjusting for age, sex, and principal components of genetic ancestry, was conducted to assess the associations between single nucleotide polymorphisms (SNPs) and VCDR. We imputed SNPs from the 1000 Genomes Project to integrate additional SNPs not directly genotyped.

**RESULTS.** We replicated two previously reported SNPs that reached GWAS significance, rs1900005 and rs7916697, in the *ATOH7-PBLD* region, as well as identified two suggestive associations in the *CDC7-TGFBR3* region on chromosome 1p22.1 and in the *ZNF770-DPH6* region on chromosome 15q14. We discovered a novel SNP, rs56238729 ( $P = 1.22 \times 10^{-13}$ ), in the *ATOH7-PBLD* region that is significantly associated with VCDR in Latino individuals. We replicated eight previously reported regions, including *COL8A1*, *CDKN2B-CDKN2BAS*, *BMP2*, and *CHEK2* ( $P < 2.17 \times 10^{-3}$ ).

**CONCLUSIONS.** Our results discovered a novel SNP that is significantly associated with VCDR in Latino individuals and confirmed previously reported loci, providing further insight into the genetic architecture of VCDR.

Keywords: GWAS, VCDR, Latino Individuals

The optic disc, situated at the back of the eye, is the location where the retinal ganglion cell axons exit the eye to form the optic nerve. Inspection of the optic disc is conducted during routine eye examinations to assess the optic nerve. In particular, the ratio of the vertical diameter of the optic cup to the vertical diameter of the optic disc, called the vertical cup-disc ratio (VCDR), is often calculated to identify and monitor possible glaucomatous damage to the optic nerve. As an important endophenotype for primary open-angle glaucoma (POAG), VCDR characterizes the extent of cupping of the optic nerve, and subsequently, the loss of retinal ganglion cell axons. In numerous epidemiologic studies investigating the prevalence of POAG, VCDR is often used as a clinical diagnostic criterion to identify either suspects or cases of POAG.<sup>1-5</sup> Due to the complex etiology of POAG, identifying the factors that influence individual quantitative traits, such as VCDR, may better elucidate the biological mechanisms underlying this disease.

Previous studies have shown substantial differences in VCDR among various ethnic populations. Overall, individuals

of African descent reported having the highest VCDR and individuals of European descent exhibiting the lowest, with Chinese and Hispanic individuals displaying VCDR measurements between African and European individuals.<sup>6,7</sup> Furthermore, heritability studies have provided additional evidence of a genetic component for VCDR determination. These studies estimate the heritability of this trait to be 48% to 66%.<sup>8,9</sup> En masse, these results suggest genetic factors have a major role in VCDR determination and specific genetic variants may influence this trait in different ethnic populations.

There have been a limited number of genome-wide association studies (GWAS) conducted to identify genetic variants associated with VCDR. A previous meta-analysis of GWAS conducted in individuals of European descent identified nine loci associated with VCDR, including *CDKN2B*, *SIX1*, *SCYL1*, *CHEK2*, *ATOH7-PBLD*, *DCLK1*, *BCAS3*, *RERE*, and *ARID3A*.<sup>10</sup> Additionally, a meta-analysis of European and Asian individuals identified several novel loci associated with VCDR, such as *CDC7-TGFBR3*, *TMTC2*, *RPAP3*, and *BMP2*.<sup>11</sup> Although these previous studies have identified a number of loci

associated with VCDR, these studies were conducted in individuals of European or Asian descent. Because specific genetic variants may be more enriched in one ethnic population compared with another, identifying genetic factors that are both common and unique to different ethnic populations will aid in elucidating racial differences in VCDR, as well as potentially uncovering the pathogenesis of various ocular diseases affecting the optic nerve. To date, there have been no reported GWAS of VCDR in Latino individuals.

Latino individuals are traditionally an underrepresented population in genetic studies, despite being the largest minority group in the United States. We hypothesize conducting a GWAS of VCDR in Latino individuals will replicate previously reported loci that are common to various ethnic populations and, potentially, identify novel loci specific to Latino individuals. Moreover, identifying genetic variants associated with VCDR in Latino individuals may help to elucidate the observed racial differences for this ocular parameter. As such, the purpose of this study was to conduct a GWAS of VCDR in Latino individuals. This study represents the first GWAS of VCDR in a Latino population.

## MATERIALS AND METHODS

### Ethics Statement

The institutional review boards at the University of Illinois at Chicago, the University of Southern California Health Sciences Campus, and the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles (UCLA) approved this research and all clinical investigation was conducted according to the principles outlined in the Declaration of Helsinki.

### Study Sample

This study was conducted using 4537 samples collected from the Los Angeles Latino Eye Study (LALES), a population-based epidemiologic study examining the prevalence, incidence, and impact of visual impairment and ocular disease in 6357 Latino individuals living in the city of La Puente, Los Angeles County, California, United States.<sup>12</sup> All study subjects were 40 years or older and written informed consent was obtained from all study participants.

### Measurements of VCDR

Stereoscopic optic disc photography was conducted using the Topcon TRC 50EX Retinal Camera (Topcon Corp. of America, Paramus, NJ, USA) with Ektachrome 100 film (Kodak, Rochester, NY, USA) and was evaluated using a stereoscopic viewer (Asahi viewer; Pentax, Englewood, CO, USA). VCDR measurements were determined by a board-certified ophthalmologist. We used the average VCDR between the left and right eyes as the final VCDR measurement for downstream analysis. If estimates were available for only one eye, the VCDR measurement of that eye was used as a proxy for the final measurement. To convert these data to a standard normal distribution, we applied an inverse normal transformation.

### Genotyping and Quality Control

Through LALES and the Mexican American Glaucoma Genetic Study, we genotyped 4996 Latino individuals using either the Illumina OmniExpress BeadChip Kit (730, 525 markers; Illumina, Inc., San Diego, CA, USA;  $n = 4278$ ) or the Illumina Hispanic/SOL BeadChip (~2.5 million markers; Illumina, Inc.;

$n = 718$ ). The Genotyping Laboratory of the Institute for Translational Genomics and Population Sciences at the Los Angeles Biomedical Research Institute at Harbor-UCLA performed the genotyping for this study. The software Illumina GenomeStudio (v2011.1; Illumina, Inc.) was used to call single nucleotide polymorphisms (SNPs). A genotyping call rate less than 97% was used to exclude study participants from further analysis. Duplicates, study participants with sex inconsistency between reported and genetically inferred sex, and missing VCDR measurements were further excluded. Implementation of these exclusion criteria resulted in 4537 study participants remaining for downstream analysis, including 3596 unrelated individuals used as a discovery set (stage 1), and 941 first-degree relatives (417 families) used as a replication set (stage 2, independent of stage 1). Quality control of the genotyped data for the study participants was conducted using the program PLINK (v1.90; available in the public domain at <https://www.cog-genomics.org/plink2>).<sup>13</sup> Overlapping SNPs between the two genotyping chips were retained for analysis and were further omitted if the minor allele frequency (MAF) was less than 1%, the call rate was less than 95%, or the Hardy-Weinberg equilibrium  $P$  values were less than  $10^{-6}$ . These exclusion criteria resulted in 576,798 SNPs remaining for downstream analysis. To facilitate the imputation process, SNPs were coded on the forward strand.

### Genotype Imputation

To identify additional SNPs associated with VCDR that were not directly genotyped, we performed genotype imputation using Shapeit2,<sup>14</sup> Minimac3 (available in the public domain at <http://genome.sph.umich.edu/wiki/Minimac3#Download>), and the 1000 Genomes Project (1KGP) reference panels. These haplotype reference panels contain approximately 39.7 million variants, substantially increasing the number of SNPs to be tested through the use of linkage disequilibrium (LD). We used the AMR+CEU+YRI reference panels (a combination of Mexican, Colombian, Puerto Rican, CEPH, and Yoruba haplotypes) for imputation because of the unique admixture of different ancestral populations in Latino individuals. This panel has previously been shown to result in the highest genotype imputation accuracy for Latino individuals.<sup>15</sup>

Using the phased genotypes from Shapeit2, genotype imputation on the phased data was conducted using Minimac3. Imputed genotypes were coded as allelic dosages (estimated counts ranging from 0–2). Low-quality imputed SNPs (i.e.,  $R_{sq} < 0.80$  and  $MAF < 1\%$ ) were filtered out. After applying these quality control parameters, 6,844,888 imputed SNPs were retained for downstream analysis.

### Statistical Analysis

We inferred principal components of genetic ancestry using the program EIGENSOFT.<sup>16</sup> To make comparisons with reference populations of known ancestry, we included reference panels of unrelated Northern Europeans (CEU,  $n = 87$ ) and West Africans (YRI,  $n = 88$ ) from the 1000 Genomes Project,<sup>17</sup> and Native Americans ( $n = 105$ ).<sup>18</sup> We retained and included the first four principal components as covariates in downstream association analyses. To assess control of population stratification, the genomic control inflation factor<sup>19</sup> was calculated and a quantile-quantile (Q-Q) plot was generated to visualize the distribution of the test statistics. Linear regression, adjusting for age, sex, and principal components of genetic ancestry, was conducted to assess the associations between SNPs and VCDR among study participants in the discovery set using PLINK (v1.90).<sup>13</sup> Additionally, an additive genetic effects model was assumed. To account for

TABLE 1. Descriptive Statistics of the Study Sample

Study	Sample Size	Females, %	Age, y, Mean (SD)	VCDR, Mean (SD)	VCDR Range
Discovery set, stage 1	3596	56.5	54.2 (9.9)	0.34 (0.18)	0.10-0.90
Replication set, stage 2	941	68.0	56.9 (12.5)	0.35 (0.19)	0.10-0.90
Total	4537	58.9	54.8 (10.6)	0.34 (0.18)	0.10-0.90

relatedness among individuals in the replication set, we used a linear mixed-effects model (Proc Mixed procedure of SAS v9.4; SAS Institute, Cary, NC, USA) to test the associations between SNPs and VCDR, adjusting for age, sex, and principal components of genetic ancestry. The empirical “sandwich” estimator and compound symmetry covariance structure were used during linear mixed-effects modeling. The software EMMAX (Efficient Mixed-Model Association Expedited; available in the public domain at <http://csg.sph.umich.edu/kang/emmax/download/>)<sup>20</sup> was used to analyze genotyped and imputed SNPs for the full study sample, the discovery and replication sets combined, using linear mixed-effects modeling to account for population stratification and relatedness, adjusting for age, sex, kinship, and principal components of genetic ancestry. Allelic dosage was used to account for genotype imputation uncertainty for imputed SNPs in EMMAX. SNPs with a  $P < 1 \times 10^{-6}$  in the discovery set were retained and analyzed in the replication set. SNPs reaching the genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ) were declared significant and SNPs reaching  $P < 1 \times 10^{-6}$  were declared suggestive during the full study sample analysis. The program *simpleM*<sup>21-23</sup> (available in the public domain at <http://simplem.sourceforge.net>) was used to identify the effective number of independent tests as a multiple testing correction method for the replication of previously published loci. Conditional association analysis was performed by including the lead SNP as a covariate in the regression model. Graphing was performed using R<sup>24</sup> (available in the public domain at <https://www.r-project.org>) and LocusZoom<sup>25</sup> (available in the public domain at <http://csg.sph.umich.edu/locuszoom/>) (hg19/1KGP 2014 AMR).

### Pathway Analysis

We performed pathway analysis using SKAT-O<sup>26</sup> (available in the public domain at <https://www.hsph.harvard.edu/skat/download/>) and QIAGEN's Ingenuity Pathway Analysis (IPA)<sup>27</sup> (QIAGEN, Redwood City, CA, USA) on the maximum number of unrelated individuals from both the discovery and replication sets to identify canonical pathways influencing VCDR. Based on the genomic positions of the GRCh37/hg19 assembly, directly genotyped SNPs were mapped to autosomal genes and a  $\pm 50$  kb gene boundary was used to capture proximal regulatory and other functional elements influencing gene regulation. Gene-set associations were conducted using SKAT-O,<sup>26</sup> adjusting for age, sex, and principal components of genetic ancestry. The commercial software IPA analyzed genes associated with VCDR for the enrichment of canonical pathways.<sup>27</sup> Significantly enriched canonical pathways,  $P < 0.05$  after Benjamini-Hochberg multiple testing adjustment,<sup>28</sup> were reported.

## RESULTS

### Study Sample

Table 1 presents the descriptive statistics for the overall study population, as well as the discovery (stage 1) and replication


(stage 2) sets separately. For the entire study sample, the mean (SD) age was 54.8 (10.6) years, with the mean age of the discovery and replication sets as 54.2 (9.9) years and 56.9 (12.5) years, respectively. The proportion of females in the entire study was 58.9%: 56.5% in the discovery set and 68.0% in the replication set. Together, the average VCDR (SD) was 0.34 (0.18; range, 0.10-0.90), with the average of the discovery and replication sets as 0.34 (0.18; range, 0.10-0.90) and 0.35 (0.19; range, 0.10-0.90), respectively.

### Genome-Wide Association Results

The genomic control inflation factor<sup>19</sup> was moderate,  $\lambda = 1.03$ . Supplementary Figure S1 displays the Q-Q plot of the observed  $P$  values versus the expected  $P$  values. As seen in the plot, the observed  $P$  values do not deviate from the null, except at the extreme tail. Both the genomic control inflation factor and the Q-Q plot indicate proper control of population stratification in this sample of Latino individuals.

Figure 1 displays a Manhattan plot of the genome-wide  $P$  values from the discovery set association analysis. The results for the top SNPs ( $P < 1 \times 10^{-6}$ ) are summarized in Table 2. One SNP, rs1900005 ( $P = 4.17 \times 10^{-8}$ , GRCh37/hg19 position 69,998,055), on chromosome 10q21.3 reached the GWAS significance level  $P < 5 \times 10^{-8}$ . The minor allele A (MAF = 0.36) was associated with a reduction in VCDR with  $\beta$  (SE) =  $-0.13$  (0.02). This SNP is located 6.2 kb upstream of the *ATOH7* (atonal bHLH transcription factor 7) gene and 44 kb downstream of the *PBLD* (phenazine biosynthesis-like protein domain containing) gene. The second most significant SNP, rs7916697 ( $P = 5.44 \times 10^{-8}$ , GRCh37/hg19 position 69,991,853), is located 6.2 kb upstream of rs1900005 and was borderline GWAS significant. This SNP is situated in the 5' untranslated region (5'UTR) of *ATOH7*. The minor allele A of rs7916697 (MAF = 0.38) is associated with a decrease in VCDR with  $\beta$  (SE) =  $-0.13$  (0.02). The third most significant SNP is rs16960773 ( $P = 3.15 \times 10^{-7}$ , GRCh37/hg19 position 35,604,502), located on chromosome 15q14 and situated 324 kb upstream of *ZNF770* (zinc finger protein 770) and 53.2 kb downstream of *DPH6* (diphthamine biosynthesis 6). The minor allele G (MAF = 0.08) is associated with a reduction in VCDR with  $\beta$  (SE) =  $-0.23$  (0.04). The last most significant SNP is rs1192419 ( $P = 4.85 \times 10^{-7}$ , GRCh37/hg19 position 92,080,059), located on chromosome 1p22.1 and positioned 88.7 kb downstream of *CDC7* (cell division cycle 7) and 65.8 kb downstream of *TGFBR3* (transforming growth factor, beta receptor III). The minor allele A (MAF = 0.29) of rs1192419 is associated with an increase in VCDR with  $\beta$  (SE) = 0.13 (0.03).

We then analyzed these top SNPs in the replication set using linear mixed-effects models. As displayed in Table 2, the direction of effect for the top four SNPs are consistent with the directions observed in the discovery set. The associations for three SNPs (rs1192419, rs7916697, and rs1900005) were strengthened when the full study sample was analyzed. In addition to rs1900005 remaining significant, rs7916697 also became genome-wide significant ( $P = 1.97 \times 10^{-11}$ ) and rs1192419 became borderline genome-wide significant ( $P = 9.56 \times 10^{-8}$ ) after analyzing the discovery and replication sets together. The SNPs rs7916697 and rs1900005 have previously



**FIGURE 1.** Manhattan plot displaying the  $-\log_{10}(P)$  values for the association between VCDR and the 576,798 SNPs in the discovery set (stage 1). The red and blue horizontal dotted lines indicate genome-wide significant associations ( $P = 5 \times 10^{-8}$ ) and suggestive associations ( $P = 1 \times 10^{-6}$ ), respectively. Previously reported and novel loci associated with VCDR are shown in dark gray (*CDC7-TGFBFR3* and *ATOH7-PBLD*) and black (*ZNF770-DPH6*), respectively. Single nucleotide polymorphisms are plotted by genomic position.

been reported to be associated with VCDR in European and Asian individuals and the results reported in this study confirm these associations in a Latino population.

**Results From Imputed SNPs**

To interrogate additional SNPs not directly genotyped, we performed genotype imputation on the full study sample. After retaining SNPs of high quality ( $R_{sq} \geq 0.80$ ), no additional genomic regions reached GWAS significance. Within the *ATOH7-PBLD* region, numerous imputed SNPs reached genome-wide significance, including several SNPs more significant than those directly genotyped (Supplementary Table S1). The most significant SNP in this region is rs56238729 ( $P = 1.22 \times 10^{-13}$ ,  $R_{sq} = 0.98$ ), located 9.8 kb downstream of rs7916697. This SNP represents a novel association with VCDR. The regional SNP association plot for the *ATOH7-PBLD* region is presented in Figure 2A. Genotyped SNPs are plotted as squares, and imputed SNPs as circles.

**Conditional Analysis**

To determine whether additional SNPs contribute to the VCDR association, we conducted conditional analysis in the *ATOH7-*

*PBLD* region. As shown in Figure 2B, conditioning on the most significant SNP, rs56238729, by including this SNP as a covariate into linear regression models resulted in all immediate SNP associations to be reduced toward the null with no other SNP remaining significant. These data suggest rs56238729 is the leading SNP of the VCDR association and further nullifies the associations of surrounding SNPs in the *ATOH7-PBLD* region, including SNPs that have previously been reported.

**Analysis of Previously Reported Loci for VCDR**


We investigated previously reported VCDR loci identified in populations of European and Asian descent to determine whether these associations are consistent in a Latino population. Table 3 summarizes these results. Of the previously reported SNPs, 25 SNPs exhibited high imputation quality ( $R_{sq} \geq 0.80$ ) and when further analyzed, we observed 32% (8/25) having a  $P < 0.05$  in our Latino population. Furthermore, we observed consistent directions of associations with all previous SNPs, except one (rs301801). To account for multiple testing and to avoid penalties associated with a traditional Bonferroni correction, we used *simpleM*<sup>21-23</sup> to calculate the effective number of independent tests. This method identified 23

**TABLE 2.** Summary Results for the Top-Ranking Genotyped SNPs Associated With VCDR in Latino Individuals


SNP	Chr	Position	Gene	A1/A2	MAF	Discovery		Replication		Entire Sample, P Value
						$\beta$	P Value	$\beta$	P Value	
rs1192419	1	92,080,059	<i>CDC7-TGFBFR3</i>	A/G	0.29	0.13	$4.85 \times 10^{-07}$	0.10	$6.25 \times 10^{-02}$	$9.56 \times 10^{-08}$
rs7916697	10	69,991,853	<i>ATOH7</i>	A/G	0.38	-0.13	$5.44 \times 10^{-08}$	-0.20	$4.07 \times 10^{-05}$	$1.97 \times 10^{-11}$
rs1900005	10	69,998,055	<i>ATOH7-PBLD</i>	A/C	0.36	-0.13	$4.17 \times 10^{-08}$	-0.21	$1.97 \times 10^{-05}$	$6.41 \times 10^{-12}$
rs16960773	15	35,604,502	<i>ZNF770-DPH6</i>	G/A	0.08	-0.23	$3.15 \times 10^{-07}$	-0.11	$1.95 \times 10^{-01}$	$9.63 \times 10^{-07}$

SNPs with  $P < 1 \times 10^{-6}$  in the discovery set are included in the table and were analyzed in the replication set. Gene name is in boldface if the SNP is located inside the gene. Single nucleotide polymorphism positions are according to GRCh37/hg19. Chr, chromosome; A1/A2, allele 1/allele 2.

(A)



(B)



**FIGURE 2.** Regional SNP association plots for the *ATOH7-PBLD* region. (A) The most significant directly genotyped SNP, rs1900005, using the entire study sample is plotted in *purple*. Genotyped and imputed SNPs ( $R_{sq} \geq 0.80$ ) are plotted as *squares* and *circles*, respectively. Genes are shown below the SNPs and the *arrows* indicate the strand orientation for each gene. The color coding in the plot represents the level of LD with rs1900005. After imputation, rs56238729 is the most significant SNP in the *ATOH7-PBLD* region. (B) Regional SNP association plot conditioning on rs56238729, the most significant SNP in the *ATOH7-PBLD* region.

TABLE 3. Comparison With Previously Reported SNPs Associated With VCDR in Latino Individuals

SNP ID	Chr	Position	Genes Nearby	Previously Reported			Latino Individuals				Consistency of			Most Significant Hits $\pm$ 100 kb		
				Effect Allele	Freq	$\beta$	Reference	A1/A2	AF1	$\beta$	P Value	Imputed	Direction	SNP ID	Position	P Value
rs301801	1	8495945	<i>RERE</i>	C/T	0.33	0.01	11	T/C	0.79	0.01	$6.67 \times 10^{-01}$	Y	N	rs2784739	8497558	$1.66 \times 10^{-01}$
rs12025126	1	8759554	<i>RERE</i>	C	0.28	-0.01	10	T/C	0.59	0.00	$8.85 \times 10^{-01}$	Y	Y	rs4908777	8804237	$1.00 \times 10^{-01}$
rs4658101	1	92077409	<i>CDC7-IGFBR3</i>	A/G	0.18	0.02	11	A/G	0.29	0.12	<b><math>4.58 \times 10^{-07}</math></b>	Y	Y	rs11924119	92080059	$9.56 \times 10^{-08}$
rs2623325	3	99131755	<i>COL8A1</i>	A/C	0.13	0.02	11	C/A	0.77	-0.04	$8.67 \times 10^{-02}$	Y	Y	rs11573333	99071153	$3.86 \times 10^{-04}$
rs17658229	5	172191052	<i>DUSP1</i>	C/T	0.05	-0.02	11	T/C	0.99	0.05	$5.88 \times 10^{-01}$	Y	Y	rs2291045	172233065	$3.05 \times 10^{-02}$
rs17756712	6	625071	<i>EXOC2</i>	G/A	0.18	0.01	11	A/G	0.82	-0.05	$6.73 \times 10^{-02}$	Y	Y	rs4960092	597871	$5.33 \times 10^{-02}$
rs868153	6	122389955	<i>HSF2</i>	G/T	0.36	-0.01	11	T/G	0.74	0.05	$5.94 \times 10^{-02}$	Y	Y	rs15212244	122294945	$6.23 \times 10^{-04}$
rs1063192	9	22003367	<i>CDKN2B</i>	G	0.45	-0.01	10	G/A	0.19	-0.09	<b><math>9.86 \times 10^{-04}</math></b>	N	Y	rs1063192	22003367	$9.86 \times 10^{-04}$
rs7865618	9	22031005	<i>CDKN2BAS</i>	G/A	0.43	-0.01	11	G/A	0.19	-0.09	<b><math>7.25 \times 10^{-04}</math></b>	Y	Y	rs1063192	22003367	$9.86 \times 10^{-04}$
rs1900005	10	69998055	<i>ATOH7</i>	A/C	0.23	-0.02	11	A/C	0.36	-0.15	<b><math>6.41 \times 10^{-12}</math></b>	N	Y	rs1900005	69998055	$6.41 \times 10^{-12}$
rs1900004	10	70000881	<i>ATOH7-PBLD</i>	T	0.22	-0.01	10	C/T	0.64	0.15	<b><math>1.50 \times 10^{-12}</math></b>	Y	Y	rs1900005	69998055	$6.41 \times 10^{-12}$
rs7072574	10	96036306	<i>PLCE1</i>	A/G	0.33	0.01	11	G/A	0.72	-0.02	$4.87 \times 10^{-01}$	Y	Y	rs11187842	96052511	$5.63 \times 10^{-05}$
rs17146964	11	65249145	<i>SCYL1</i>	G	0.21	-0.01	10	A/G	0.86	0.03	$2.89 \times 10^{-01}$	N	Y	rs619586	65266169	$3.92 \times 10^{-02}$
rs1346	11	65337251	<i>SSSCA1</i>	T/A	0.19	-0.01	11	A/T	0.86	0.04	$2.30 \times 10^{-01}$	Y	Y	rs619586	65266169	$3.92 \times 10^{-02}$
rs4936099	11	130280725	<i>ADAMTS8</i>	C/A	0.42	-0.01	11	C/A	0.29	-0.01	$8.02 \times 10^{-01}$	Y	Y	rs10736582	130241003	$1.51 \times 10^{-02}$
rs11168187	12	48044011	<i>RPAP3</i>	G/A	0.16	-0.01	11	A/G	0.87	0.01	$8.12 \times 10^{-01}$	N	Y	rs757282	48130578	$4.83 \times 10^{-06}$
rs10862688	12	83922912	<i>TMTC2</i>	G/A	0.45	0.01	11	A/G	0.75	0.00	$9.19 \times 10^{-01}$	N	Y	rs904091	83950668	$5.02 \times 10^{-04}$
rs1926320	13	36652617	<i>DCLK1</i>	C	0.24	0.01	10	T/C	0.69	-0.02	$3.72 \times 10^{-01}$	Y	Y	rs1887829	36721724	$1.24 \times 10^{-01}$
rs4901977	14	60789176	<i>SIX1-SIX6</i>	T/C	0.31	0.01	11	C/T	0.75	-0.05	$5.27 \times 10^{-02}$	N	Y	rs4901977	60789176	$5.27 \times 10^{-02}$
rs10483727	14	61072875	<i>SIX1</i>	T	0.4	0.01	10	T/C	0.35	0.03	$1.33 \times 10^{-01}$	N	Y	rs1010053	61005625	$6.08 \times 10^{-02}$
rs1345467	16	51482321	<i>SALL1</i>	G/A	0.27	0.01	11	G/A	0.17	0.06	$2.63 \times 10^{-02}$	N	Y	rs8053277	51469726	$1.38 \times 10^{-02}$
rs8068952	17	59286644	<i>BCAS3</i>	G	0.24	-0.01	10	G/C	0.19	-0.03	$3.51 \times 10^{-01}$	Y	Y	rs7212615	59323318	$1.26 \times 10^{-02}$
rs2159128	19	950380	<i>ARID3A</i>	G	0.13	-0.02	10	G/T	-	-	-	NA	NA	rs1056144	974967	$2.11 \times 10^{-01}$
rs6054374	20	6578556	<i>BMP2</i>	T/C	0.42	-0.01	11	C/T	0.46	0.06	$1.02 \times 10^{-02}$	Y	Y	rs6140015	6487524	$4.37 \times 10^{-04}$
rs1547014	22	29100711	<i>CHEK2</i>	T	0.29	-0.01	10, 11	T/C, $\beta = -0.013$	0.33	-0.05	$3.43 \times 10^{-02}$	N	Y	rs4035540	29087041	$3.44 \times 10^{-05}$
rs5756813	22	38175477	<i>CARD10</i>	G/T	0.39	0.01	11	G/T	0.41	0.01	$5.74 \times 10^{-01}$	Y	Y	rs5750472	38081747	$8.86 \times 10^{-02}$

Additional allele, frequency, and effect size information is given in parentheses for SNPs with multiple references. The frequency of allele 1 is given for our Latino sample and is modeled as the effect allele. To correct for multiple testing for correlated SNPs, the program *simpleM* was used, and identified 25 independent tests, resulting in a Bonferroni correction  $P$  value of  $0.05/23 = 2.17 \times 10^{-3}$ . Shown in bold are  $P$  values meeting this threshold. Using directly genotyped SNPs, the most significant hit within  $\pm 100$  kb of previously reported SNPs are listed ( $P$  values  $< 2.17 \times 10^{-3}$  are italicized). All SNPs, except rs2159128, had an  $Rsq \geq 0.80$  from Minimac3. Most SNPs exhibited consistent direction of effect, except for rs301801. Single nucleotide polymorphism positions are according to GRCh37/hg19. Freq, frequency.

independent tests, resulting in a Bonferroni correction significance level of  $P = 2.17 \times 10^{-3}$ . We were able to replicate five index SNPs in three regions (*CDC7-TGFBR3*, *CDKN2B-CDKN2BAS*, and *ATOH7-PBLD*) after multiple testing correction (shown in boldface in Table 3). To replicate genomic regions associated with VCDR, we extracted the most significant directly genotyped SNP within  $\pm 100$  kb of the previously reported SNPs. This approach identified an additional five SNPs in five regions surviving the multiple testing correction, replicating the associations between VCDR and the *COL8A1*, *HSF2*, *RPAP3*, *TMTC2*, and *BMP2* regions.

### Pathway Analysis

To determine whether canonical pathways were enriched with genes associated with VCDR, we performed pathway analysis using IPA. After adjusting for multiple testing, the only pathway significantly associated with VCDR was the “pathogenesis of multiple sclerosis (MS)” pathway ( $P = 7.41 \times 10^{-3}$ ). Of the nine genes comprising this pathway, five genes from our dataset overlapped with these genes, including *CCL3*, *CCL4*, *CXCL9*, *CXCL10*, and *CXCL11*.

### DISCUSSION

This study represents the first GWAS conducted on VCDR in Latino individuals. We identified two genome-wide significant SNPs, rs1900005 and rs7916697, associated with VCDR, confirming the involvement of the *ATOH7-PBLD* region. We also identified suggestive associations in the *CDC7-TGFBR3* and *ZNF770-DPH6* regions. We discovered a novel SNP, rs56238729, in the *ATOH7-PBLD* region to be significantly associated with VCDR in Latino individuals after genotype imputation from the 1KGP reference panels. Moreover, we were able to replicate genomic regions previously associated with VCDR, including *COL8A1*, *HSF2*, *RPAP3*, *TMTC2*, and *BMP2*. Results from our pathway analysis identified one canonical pathway associated with VCDR.

The most significant SNPs in our study reside in the *ATOH7-PBLD* region. Previous GWAS studies, including Ramdas et al.<sup>10</sup> and Springelkamp et al.,<sup>11</sup> identified many SNPs in the *ATOH7-PBLD* region to be associated with VCDR. In addition to VCDR, earlier GWAS have also associated this region with optic disc area,<sup>10,29–31</sup> cup area,<sup>29,30</sup> and POAG.<sup>10</sup> Both rs1900005 and rs7916697, the most and second most significant SNPs in our study, respectively, have previously been associated with VCDR.<sup>11</sup> In particular, rs7916697 resides in the 5'UTR region of *ATOH7*, a single exon gene that plays a role in retinal ganglion cell development.<sup>32</sup> Moreover, rs7916697 has been associated with a reduction in optic disc area<sup>31</sup> and was identified to have a significant interactive effect with rs1063192 in an Afro-Caribbean population, resulting in a reduction in POAG risk.<sup>33</sup> Taken together, our results are consistent with previous studies of these SNPs being strongly associated with glaucoma-related quantitative traits and may have a biological role in the pathogenesis of POAG.

The third and fourth most significant SNPs indicate suggestive associations in the *CDC7-TGFBR3* and *ZNF770-DPH6* regions, respectively. Similar to the previous region, the *CDC7-TGFBR3* region has been reported to be associated with VCDR,<sup>11</sup> optic disc area,<sup>10,31</sup> and POAG.<sup>34</sup> Moreover, expression of both *CDC7* and *TGFBR3* have been observed in numerous human ocular tissues, most notably the optic disc and optic nerve.<sup>34</sup> The SNP rs1192419 has specifically been associated with VCDR<sup>11</sup> and an increase in disc area.<sup>29</sup> Additionally, common variants within the genomic region on chromosome 15q14, in which *ZNF770-DPH6* resides, has

previously been associated with refractive error and myopia.<sup>35</sup> This study independently confirms the associations of rs1900005 and rs7916697 in the *ATOH7-PBLD* region with VCDR in a sample of Latino individuals and suggests additional loci in the *CDC7-TGFBR3* and *ZNF770-DPH6* regions.

Although ophthalmologists routinely assess the VCDR to diagnose and monitor the progression of POAG, the cupping of the optic nerve may not solely be a result of glaucoma and may result from other conditions, such as optic neuritis.<sup>36</sup> Our pathway results implicate an association between the pathogenesis of MS and VCDR. Multiple sclerosis is a demyelinating disease of the central nervous system that commonly affects vision. Patients with MS were found to have a higher VCDR compared with healthy controls, suggesting enlarging of the optic cup due to the thinning of the retinal nerve fiber layer may be explained by the predilection of the disease to afflict the optic nerves.<sup>37</sup> Moreover, several of the genes included in this pathway code for chemokines that were shown to be at higher concentrations in the aqueous humor of glaucomatous eyes compared with cataract controls.<sup>38</sup> Collectively, our pathway results suggest the biological mechanisms influencing VCDR and MS may share common genetic constituents.

This is the first GWAS of VCDR in Latino individuals and several limitations exist. First, the Latino population is historically understudied. As far as we know, our dataset is currently the only Latino genetic dataset with ophthalmic phenotypes. Furthermore, the three-way admixture of Latino individuals makes it even more challenging in genetics research (Supplementary Fig. S2).<sup>15,39,40</sup> Using STRUCTURE (available in the public domain at <http://pritchardlab.stanford.edu/structure.html>),<sup>41,42</sup> we estimated that our Latino subjects on average had 3%, 53%, and 44% African, European, and Native American ancestries, respectively (Supplementary Fig. S3). We performed a fixed-effects meta-analysis for the discovery and replication sets on the top genotyped SNPs using METAL<sup>43</sup> (available in the public domain at <http://csg.sph.umich.edu/abecasis/Metal/download/>) and obtained similar results as EMMAX (Supplementary Table S2). These results suggest population stratification and genetic relatedness were properly controlled for in our analysis, despite Latino individuals being a three-way admixed population. However, we emphasize the need for replication in an independent Latino cohort. Second, we did not conduct secondary analyses adjusting for disc area, an ocular parameter known to be correlated with VCDR.<sup>44</sup> Unfortunately, at the time of the VCDR data collection, disc area was not collected. Given a previously reported reduction in significance for VCDR-associated variants after adjusting for disc area,<sup>11</sup> a similar trend may be observed for our results.

In conclusion, in the first GWAS of VCDR in Latino individuals, we discovered a novel SNP that is significantly associated with VCDR in Latino individuals. In addition, two SNPs reached genome-wide significance, replicating associations in the *ATOH7-PBLD* region. We were also able to replicate associations with several previously reported genomic regions for VCDR in this population. Our pathway results identified a novel association between pathogenesis of MS and VCDR, suggesting potential shared genetic factors influencing both VCDR and MS. The findings from this study suggest that many genetic factors influencing VCDR are shared among ethnic populations.

### Acknowledgments

The authors thank the study participants from LALES and the staff who aided in data collection and processing.

Supported in part by National Institutes of Health (NIH; Bethesda, MD, USA) Grants R01EY022651 (XG), U10EY011753 (RV), and P30EY001792 (departmental core grant). The provision of



genotyping data was supported in part by the National Center for Advancing Translational Sciences Grant UL1TR000124 and National Institute of Diabetes and Digestive and Kidney Diseases Diabetes Research Center Grant DK063491 to the Southern California Diabetes Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.

Disclosure: **D.R. Nannini**, None; **M. Torres**, None; **Y.-D.I. Chen**, None; **K.D. Taylor**, None; **J.I. Rotter**, None; **R. Varma**, None; **X. Gao**, None

## References

1. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology*. 2004;111:1439-1448.
2. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology*. 1996;103:1661-1669.
3. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Arch Ophthalmol*. 2001;119:1819-1826.
4. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. *Arch Ophthalmol*. 1994;112:821-829.
5. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99:1499-1504.
6. Knight OJ, Girkin CA, Budenz DL, Durbin MK, Feuer WJ, Cirrus OCTNDG. Effect of race, age, and axial length on optic nerve head parameters and retinal nerve fiber layer thickness measured by Cirrus HD-OCT. *Arch Ophthalmol*. 2012;130:312-318.
7. Varma R, Tielsch JM, Quigley HA, et al. Race-, age-, gender-, and refractive error-related differences in the normal optic disc. *Arch Ophthalmol*. 1994;112:1068-1076.
8. Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci*. 2004;45:59-62.
9. Charlesworth J, Kramer PL, Dyer T, et al. The path to open-angle glaucoma gene discovery: endophenotypic status of intraocular pressure, cup-to-disc ratio, and central corneal thickness. *Invest Ophthalmol Vis Sci*. 2010;51:3509-3514.
10. Ramdas WD, van Koolwijk LM, Ikram MK, et al. A genome-wide association study of optic disc parameters. *PLoS Genet*. 2010;6:e1000978.
11. Springelkamp H, Hohn R, Mishra A, et al. Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. *Nat Commun*. 2014;5:4883.
12. Varma R, Paz SH, Azen SP, et al. The Los Angeles Latino Eye Study: design, methods, and baseline data. *Ophthalmology*. 2004;111:1121-1131.
13. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7.
14. Delaneau O, Marchini J; 1000 Genomes Project Consortium. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. *Nat Commun*. 2014;5:3934.
15. Gao X, Haritunians T, Marjoram P, et al. Genotype imputation for Latinos using the HapMap and 1000 Genomes Project Reference Panels. *Front Genet*. 2012;3:117.
16. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet*. 2006;2:e190.
17. Abecasis GR, Auton A, et al.; 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012;491:56-65.
18. Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. *Am J Hum Genet*. 2007;80:1171-1178.
19. Devlin B, Roeder K. Genomic control for association studies. *Biometrics*. 1999;55:997-1004.
20. Kang HM, Sul JH, Service SK, et al. Variance component model to account for sample structure in genome-wide association studies. *Nat Genet*. 2010;42:348-354.
21. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genet Epidemiol*. 2008;32:361-369.
22. Gao X. Multiple testing corrections for imputed SNPs. *Genet Epidemiol*. 2011;35:154-158.
23. Gao X, Becker LC, Becker DM, Starmer JD, Province MA. Avoiding the high Bonferroni penalty in genome-wide association studies. *Genet Epidemiol*. 2010;34:100-105.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
25. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010;26:2336-2337.
26. Lee S, Emond MJ, Bamshad MJ, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet*. 2012;91:224-237.
27. QIAGEN. Ingenuity Pathway Analysis. Available at: <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/>.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*. 1995;57:289-300.
29. Springelkamp H, Mishra A, Hysi PG, et al. Meta-analysis of genome-wide association studies identifies novel loci associated with optic disc morphology. *Genet Epidemiol*. 2015;39:207-216.
30. Macgregor S, Hewitt AW, Hysi PG, et al. Genome-wide association identifies ATOH7 as a major gene determining human optic disc size. *Hum Mol Genet*. 2010;19:2716-2724.
31. Khor CC, Ramdas WD, Vithana EN, et al. Genome-wide association studies in Asians confirm the involvement of ATOH7 and TGFBR3, and further identify CARD10 as a novel locus influencing optic disc area. *Hum Mol Genet*. 2011;20:1864-1872.
32. Brown NL, Dagenais SL, Chen CM, Glaser T. Molecular characterization and mapping of ATOH7, a human atonal homolog with a predicted role in retinal ganglion cell development. *Mamm Genome*. 2002;13:95-101.
33. Cao D, Jiao X, Liu X, et al. CDKN2B polymorphism is associated with primary open-angle glaucoma (POAG) in the Afro-Caribbean population of Barbados, West Indies. *PLoS One*. 2012;7:e39278.
34. Li Z, Allingham RR, Nakano M, et al. A common variant near TGFBR3 is associated with primary open angle glaucoma. *Hum Mol Genet*. 2015;24:3880-3892.
35. Solouki AM, Verhoeven VJ, van Duijn CM, et al. A genome-wide association study identifies a susceptibility locus for refractive errors and myopia at 15q14. *Nat Genet*. 2010;42:897-901.
36. Rebolleda G, Noval S, Contreras I, Arnalich-Montiel F, Garcia-Perez JL, Munoz-Negrete FJ. Optic disc cupping after optic

- neuritis evaluated with optic coherence tomography. *Eye (Lond)*. 2009;23:890-894.
37. Syc SB, Warner CV, Saidha S, et al. Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis. *J Neurol Sci*. 2011;302:19-24.
  38. Chua J, Vania M, Cheung CM, et al. Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes. *Mol Vis*. 2012;18:431-438.
  39. Gao X, Gauderman WJ, Marjoram P, et al. Native American ancestry is associated with severe diabetic retinopathy in Latinos. *Invest Ophthalmol Vis Sci*. 2014;55:6041-6045.
  40. Nannini D, Torres M, Chen YD, et al. African ancestry is associated with higher intraocular pressure in Latinos. *Ophthalmology*. 2016;123:102-108.
  41. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. *Genetics*. 2003;164:1567-1587.
  42. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. *Genetics*. 2000;155:945-959.
  43. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190-2191.
  44. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR, Jansonius NM. Heidelberg Retina Tomograph (HRT3) in population-based epidemiology: normative values and criteria for glaucomatous optic neuropathy. *Ophthalmic Epidemiol*. 2011;18:198-210.